文献リスト

1) 多田羅勝義, 神野 進. Duchenne型筋ジストロフィーの人工呼吸管理とその予後. 医療. 2008; 62: 566-71

2) Matsumura T, Saito T, Fujimura H, et al. Cardiac troponin I for accurate evaluation of cardiac status in myopathic patients. Brain Dev. 2007; 29: 496-501

3) 松村 剛, 吉尾 卓, 山本啓二, 他. 筋ジストロフィー患者では高率に抗β1アドレナリン受容体抗体が存在する. 臨床神経学. 2006; 46: 687-92

4) Kajimoto H, Ishigaki K, Okumura K, et al. Beta-blocker therapy for cardiac dysfunction in patients with muscular dystrophy. Circ J. 2006; 70: 991-4

5) Rhodes J, Margossian R, Darras BT, et al. Safety and efficacy of carvedilol therapy for patients with dilated cardiomyopathy secondary to muscular dystrophy. Pediatr Cardiol. 2008; 29: 343-51

6) 松村 剛. 筋ジストロフィーの心不全治療─β遮断薬の多施設臨床研究─. 厚生労働省精神・神経疾患研究委託費 筋ジストロフィー治療のエビデンス構築に関する臨床研究. 東京: 新星社; 2008. p. 41-7

7) Mori K, Manabe T, Nii M, et al. Plasma levels of natriuretic peptide and echocardiographic parameters in patients with Duchenne's progressive muscular dystrophy. Pediatr Cardiol. 2002; 23: 160-6

8) Demachi J, Kagaya Y, Watanabe J, et al. Characteristics of the increase in plasma brain natriuretic peptide level in left ventricular systolic dysfunction, associated with muscular dystrophy in comparison with idiopathic dilated cardiomyopathy. Neuromuscul Disord. 2004; 14: 732-9

9) Tamura T, Shibuya N, Hashiba K, et al. Evaluation of myocardial damage in Duchenne's muscular dystrophy with thallium-201 myocardial SPECT. Jpn Heart J. 1993; 34: 51-61

10) Momose M, Iguchi N, Imamura K, et al. Depressed myocardial fatty acid metabolism in patients with muscular dystrophy. Neuromuscul Disord. 2001; 11: 464-9

11) Friedrich MG. Magnetic resonance imaging in cardiomyopathies. J Cardiovasc Magn Reson. 2000; 2: 67-82

12) Ashford MW Jr, Liu W, Lin SJ, et al. Occult cardiac contractile dysfunction in dystrophin-deficient children revealed by cardiac magnetic resonance strain imaging. Circulation. 2005; 112: 2462-7

13) Meune C, Pascal O, Becane HM, et al. Reliable detection of early myocardial dysfunction by tissue Doppler echocardiography in Becker muscular dystrophy. Heart. 2004; 90: 947-8

14) Chetboul V, Escriou C, Tessier D, et al. Tissue Doppler imaging detects early asymptomatic myocardial abnormalities in a dog model of Duchenne's cardiomyopathy. Eur Heart J. 2004; 25: 1934-9

15) Ogata H, Nakatani S, Ishikawa Y, et al. Myocardial strain changes in Duchenne muscular dystrophy without overt cardiomyopathy. Int J Cardiol. 2007; 115: 190-5

16) Mori K, Hayabuchi Y, Inoue M, et al. Myocardial strain imaging for early detection of cardiac involvement in patients with Duchenne's progressive muscular dystrophy. Echocardiography. 2007; 24: 598-608

17) Merlet P, Valette H, Dubois-Rande JL, et al. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med. 1992; 33: 471-7

18) Clark AN, Beller GA. The present role of nuclear cardiology in clinical practice. Q J Nucl Med Mol Imaging. 2005; 49: 43-58

19) Kakuchi H, Sasaki T, Ishida Y, et al. Clinical usefulness of 123I meta-iodobenzylguanidine imaging in predicting the effectiveness of beta blockers for patients with idiopathic dilated cardiomyopathy before and soon after treatment. Heart. 1999; 81: 148-52

20) Yamazaki J, Muto H, Kabano T, et al. Evaluation of beta-blocker therapy in patients with dilated cardiomyopathy--Clinical meaning of iodine 123-metaiodobenzylguanidine myocardial single-photon emission computed tomography. Am Heart J. 2001; 141: 645-52

21) Baba A, Yoshikawa T, Chino M, et al. Characterization of anti-myocardial autoantibodies in Japanese patients with dilated cardiomyopathy. Jpn Circ J. 2001; 65: 867-73

22) Jahns R, Boivin V, Siegmund C, et al. Autoantibodies activating human beta1-adrenergic receptors are associated with reduced cardiac function in chronic heart failure. Circulation. 1999; 99: 649-54

23) Iwata M, Yoshikawa T, Baba A, et al. Autoantibodies against the second extracellular loop of beta1-adrenergic receptors predict ventricular tachycardia and sudden death in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 2001; 37: 418-24

24) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med. 1991; 325: 293-302

25) Kjekshus J, Swedberg K, Snapinn S. Effects of enalapril on long-term mortality in severe congestive heart failure. CONSENSUS Trial Group. Am J Cardiol. 1992; 69: 103-7

26) Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet. 1997; 349: 747-52

27) Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000; 355: 1582-7

28) Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001; 345: 1667-75

29) Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003; 362: 759-66

30) Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet. 1993; 342: 1441-6

31) Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U. S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996; 334: 1349-55

32) The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999; 353: 9-13

33) Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001; 344: 1651-8

34) Remme WJ, Riegger G, Hildebrandt P, et al. The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction. The carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial (CARMEN). Cardiovasc Drugs Ther. 2004; 18: 57-66

35) 田村拓久, 澁谷統壽, 飯田光男, 他. Duchenne型筋ジストロフィー患者の慢性心機能障害に対するカプトリル治療の臨床評価. 臨床医薬. 1996; 12: 3635-46

36) Ishikawa Y, Bach JR, Minami R. Cardioprotection for Duchenne's muscular dystrophy. Am Heart J. 1999; 137: 895-902

37) 齊藤利雄, 松村 剛, 宮井一郎, 他. Duchenne型筋ジストロフィーの左心機能障害に対するcarvedilolの臨床効果. 臨床神経. 2001; 41: 691-4

38) Ghali JK, Anand IS, Abraham WT, et al. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation. 2008; 117: 526-35

39) Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999; 341: 709-17

40) Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003; 348: 1309-21

41) Cosin J, Diez J. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail. 2002; 4: 507-13

42) 松村 剛, 齊藤利雄, 宮井一郎, 他. 著明な電解質異常と代謝性アシドーシスを示した末期心不全デュシェンヌ型筋ジストロフィーの2例. 臨床神経学. 2000; 40: 439-45

43) Yanagisawa A, Miyagawa M, Yotsukura M, et al. The prevalence and prognostic significance of arrhythmias in Duchenne type muscular dystrophy. Am Heart J. 1992; 124: 1244-50

44) Perloff JK, Stevenson WG, Roberts NK, et al. Cardiac involvement in myotonic muscular dystrophy (Steinert's disease): a prospective study of 25 patients. Am J Cardiol. 1984; 54: 1074-81

45) Nishioka SA, Martinelli Filho M, Marie S, et al. [Myotonic dystrophy and heart disease: behavior of arrhythmic events and conduction disturbances]. Arq Bras Cardiol. 2005; 84: 330-6

46) Hong JS, Ki CS, Kim JW, et al. Cardiac dysrhythmias, cardiomyopathy and muscular dystrophy in patients with Emery-Dreifuss muscular dystrophy and limb-girdle muscular dystrophy type 1B. J Korean Med Sci. 2005; 20: 283-90

47) Vohanka S, Vytopil M, Bednarik J, et al. A mutation in the X-linked Emery-Dreifuss muscular dystrophy gene in a patient affected with conduction cardiomyopathy. Neuromuscul Disord. 2001; 11: 411-3

48) Groh WJ, Groh MR, Saha C, et al. Electrocardiographic abnormalities and sudden death in myotonic dystrophy type 1. N Engl J Med. 2008; 358: 2688-97

49) Merino JL, Carmona JR, Fernandez-Lozano I, et al. Mechanisms of sustained ventricular tachycardia in myotonic dystrophy: implications for catheter ablation. Circulation. 1998; 98: 541-6

50) 松村 剛, 姜 進, 野崎園子, 他. 末期心不全DMD1例におけるミルリノンの効果. 臨床神経学. 1999; 39: 643-8

51) Suwa M, Seino Y, Nomachi Y, et al. Multicenter prospective investigation on efficacy and safety of carperitide for acute heart failure in the 'real world' of therapy. Circ J. 2005; 69: 283-90

52) Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchronization in chronic heart failure. N Engl J Med. 2002; 346: 1845-53

53) Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004; 350: 2140-50

54) Muller J, Wallukat G, Dandel M, et al. Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy. Circulation. 2000; 101: 385-91

55) Staudt A, Schaper F, Stangl V, et al. Immunohistological changes in dilated cardiomyopathy induced by immunoadsorption therapy and subsequent immunoglobulin substitution. Circulation. 2001; 103: 2681-6

56) Markham LW, Spicer RL, Khoury PR, et al. Steroid therapy and cardiac function in Duchenne muscular dystrophy. Pediatr Cardiol. 2005; 26: 768-71

57) Segers VF, Lee RT. Stem-cell therapy for cardiac disease. Nature. 2008; 451: 937-42

58) 磯村 正. 筋ジストロフィーの心筋障害 特発性拡張型心筋症の外科治療 Batista手術の現状と筋ジストロフィーへの適応. 神経内科. 2005; 62: 589-93

59) Casazza F, Brambilla G, Salvato A, et al. Cardiac transplantation in Becker muscular dystrophy. J Neurol. 1988; 235: 496-8

60) Ruiz-Cano MJ, Delgado JF, Jimenez C, et al. Successful heart transplantation in patients with inherited myopathies associated with end-stage cardiomyopathy. Transplant Proc. 2003; 35: 1513-5

61) Leprince P, Heloire F, Eymard B, et al. Successful bridge to transplantation in a patient with Becker muscular dystrophy-associated cardiomyopathy. J Heart Lung Transplant. 2002; 21: 822-4

62) Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med. 2001; 345: 1435-43

63) 許 俊鋭. 筋ジストロフィーの心筋障害 特発性拡張型心筋症の外科治療 補助人工心臓の現状と筋ジストロフィーへの適応. 神経内科. 2005; 62: 582-8

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp